Biotechnology company QUiCKR Bio is using liquid handling solutions from INTEGRA Biosciences to run its CRISPR edit confirmation assays. QUiCKR’s proprietary assays eliminate key bottlenecks of sequencing-based confirmation in CRISPR gene editing, ensuring more efficient workflows and accelerating downstream research. Quantifying the outcome of CRISPR gene editing to modify, delete or correct specific regions of DNA has traditionally been performed using costly and time-consuming NGS or droplet digital PCR (ddPCR). QUiCKR Bio, based in New York, offers pre-plated assays and cloud platform analysis for quantification of DNA sequences with NGS-level accuracy in just 20 minutes, helping pharma and biotech companies to optimise therapeutic candidates.